In breast cancer, febrile neutropenia-related admissions account for significant mortality
the ONA take:
According to a new study published in the journal Supportive Care in Cancer, researchers from the Reading Health System Department of Internal Medicine in West Reading, Pennsylvania, have found that febrile neutropenia-related hospitalizations still account for significant health care resource use, morbidity, and mortality among patients with breast cancer.
For the retrospective study, researchers sought to investigate the mean length of stay, incidence of morbidity and mortality, and health care costs associated with febrile neutropenia-related admissions of patients with breast cancer.
Researchers identified patients with breast cancer who were hospitalized for febrile neutropenia between 2009 and 2011 from the Nationwide Impact Sample database. Results showed that the mean length of stay was 5.7 days (95% CI: 5.5 - 5.9) and the mean cost of hospitalization was $37,087 (95% CI: 34,009 - 40,165).
They found that the average inhospital mortality rate during that period was 2.6% (n = 685), and age 65 years and older was associated with a higher risk of mortality (4.4% vs 1.7%; OR = 2.7; 95% CI: 2.3 - 3.1; P < 0.01). The findings suggest that febrile neutropenia accounts for significant mortality, and more effort needs to be made to reduce the cost of health care without decreasing the quality of care.
Febrile neutropenia-related hospitalizations still account for morbidity, and mortality among patients with breast cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|